NEWTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the pricing of its initial public offering of 5,333,333 shares of common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions, for gross proceeds of approximately $75 million. All of the shares are being offered by Allena. In addition, Allena has granted the underwriters a 30-day option to purchase up to an additional 800,000 shares of common stock at the initial public offering price. The shares are scheduled to begin trading on the NASDAQ Global Select Market under the ticker symbol “ALNA” on Thursday, November 2, 2017. The offering is expected to close on November 6, 2017, subject to the satisfaction of customary closing conditions.

Credit Suisse, Jefferies, and Cowen are acting as the lead book-running managers of the offering. Wedbush PacGrow is acting as the co-manager for the proposed offering.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.